Angiogenesis in inflammatory joint disease: A target for therapeutic intervention

Clinical and Experimental Immunology

Volumn 121, Issue 3, 2000, Pages 426-429

  Brenchley, P E C ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; BUCILLAMINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOKINE; DEXAMETHASONE; NONSTEROID ANTIINFLAMMATORY AGENT; RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; CYTOKINE RELEASE; ENZYME INHIBITION; GENE CONTROL; HUMAN; IMMUNOMODULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE;

ANGIOGENESIS INDUCING AGENTS; ANOXIA; ARTHRITIS; CYTOKINES; ENDOTHELIAL GROWTH FACTORS; EXTRACELLULAR MATRIX; HUMANS; LYMPHOKINES; NEOVASCULARIZATION, PATHOLOGIC; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033850716     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01299.x     Document Type: Review

References (57)

1. Angiogenesis
2. Review: Angiogenesis: Implications for rheumatoid arthritis
3. Focally regulated endothelial proliferation and cell death in human synovium
4. Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol
5. Angiogenesis inhibition suppresses collagen arthritis
6. A novel angiogenesis inhibitor suppresses rat adjuvant arthritis
7. Decreased angiogenesis and arthritic disease in rabbits treated with an alpha v beta3 antagonist
8. Tumor angiogenesis
9. Vascular endothelial growth factor (VEGF) and its receptors
10. Vascular endothelial growth factor - A cytokine modulating endothelial function in rheumatoid arthritis
11. Expression of basic fibroblast growth factor in synovial tissue from patients with rheumatoid arthritis and degenerative joint disease
12. Placenta growth factor (PlGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid
13. Rheumatoid arthritis and osteoarthritis synovial fluid effects on primary human endothelial cell cultures
14. Human neutrophils secrete vascular endothelial growth factor
15. Activated human neutrophils express vascular endothelial growth factor (VEGF)
16. Vascular permeability factor/endothelial growth factor (VPF/VEGF): Accumulation and expression in human synovial fluids and rheumatoid synovial tissue
17. Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1 beta
18. Hypoxia augments cytokine (transforming growth factor-beta (TGF-beta) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts
19. Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): Specific up-regulation by tumour necrosis factor-alpha (TNF-alpha) in synovial fluid
20. Induction of vascular endothelial growth factor gene expression by interleukin-1 beta in rat aortic smooth muscle cells
21. Interleukin 6 induces the expression of vascular endothelial growth factor
22. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells
23. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells: Synergistic interaction with hypoxia
24. Hypoxia and platelet-derived growth factor-BB synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells
25. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: A model of glioblastoma multiforme pathophysiology
26. Downregulation of vascular endothelial growth factor receptors by tumor necrosis factor-alpha in cultured human vascular endothelial cells
27. Definition of two angiogenic pathways by distinct alpha (v) integrins
28. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
29. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin
30. Hypoxia and acidosis in chronic inflammatory arthritis; relation to vascular supply and dynamic effusion pressure
31. A comparative study by morphometry of the microvasculature in normal and rheumatoid synovium
32. Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the erythropoietin gene
33. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
34. Sequencing of the human vascular endothelial growth factor (VEGF) 3' untranslated region (UTR): Conservation of five hypoxia-inducible RNA-protein binding sites
35. Genetic epidemiology of rheumatoid disease
36. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3
37. Peripheral mononuclear cells express VEGF and the VEGF receptor FLT-1
38. Genetics of tumour necrosis factor-alpha in autoimmune, infectious, and neoplastic diseases
39. Identification of polymorphisms within the vascular endothelial growth factor gene: Correlation with variation in VEGF protein production
40. Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early inflammatory arthritis
41. Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: A potentially useful laboratory marker
42. Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate
43. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules
44. Metabolism of receptor-bound and matrix-bound basic fibroblast growth factor by bovine capillary endothelial cells
45. Cellular response to transforming growth factor-betal and basic fibroblast growth factor depends on release kinetics and extracellular matrix interactions
46. Expression of the basement membrane heparan sulfate proteoglycan (perlecan) in human synovium and in cultured human synovial cells
47. Glomerular basement membrane proteoglycans are derived from a large precursor
48. Heparan sulfate proteoglycan on endothelium efficiently induces integrin-mediated T cell adhesion by immobilising chemokines in patients with rheumatoid synovitis
49. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2
50. Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis
51. Human mononuclear cells contain an endoglycosidase specific for heparan sulphate glycosaminoglycan demonstrable with the use of a specific solid-phase metabolically radiolabelled substrate
52. Subcellular localization of heparanase in human neutrophils
53. Heparanase activity in cultured endothelial cells
54. Antagonising the expression of VEGF in pathological angiogenesis
55. Clinical applications of angiogenic growth factors and their inhibitors
56. Inhibitory effects of anti-rheumatic drugs on vascular endothelial growth factor in cultured rheumatoid synovial cells
57. Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing